Late Breaking Abstract - Treatment with taladegib results in increased lung volume and regression of markers of ILD: A Phase 2a post hoc CT analysis using Brainomix e-Lung (ERS 2026) - Jul 14, 2026 - Abstract #PA804; Pres time: Sep 6, 2026; 08:00 AM - 09:30 AM; Location: PS-33; Board Number: 1; "e-Lung measures show that treatment with taladegib results in increased lung volumes and reduction in markers of ILD extent, confirming that taladegib is a promising future treatment for IPF."
Late-breaking abstract • P2a data • Retrospective data • Fibrosis • Immunology • Interstitial Lung Disease
|
|
P. George; A. Deveraj; A. DiFrancesco; G. Harston; J. Hood; J. Huetsch; C. Rennison Jones; M. de los Rios; W. Bou-Zeid; L. Lancaster
|